Grant: Idea to Innovation
Brock University
$123,930.00
Efficient chemoenzymatic synthesis of Tamiflu: Proof of principle, optimization , and development of the shortest commercial synthesis
EF 2008-09
Résumé
The proposed project is concerned with providing a short synthesis of oseltamivir phosphate (Tamiflu) with potential for producing this important antiviral agent on a commercial scale. Tamiflu is one of the few compounds effective against H5N1 influenza virus, and many world governments have stockpiled it as insurance in the event of a major breakout of avian or other forms of influenza. The amounts required for Canada and the U.S. have been estimated at 25 tons of the raw drug. Current commercial syntheses, and several academic efforts, produce Tamiflu in sequences ranging from 8 to 21 steps. Almost all syntheses originate from either natural products or other chiral pool reagents.
The first objective of the project to optimize an eight-step first-generation synthesis, recently accomplished in our laboratory, to a scale of 100 grams of Tamiflu. Provision of detailed experimental procedures will make it possible for a large-scale process group to take the scale to kilogram level and beyond. The synthesis begins with the enzymatic oxidation of a commodity chemical, bromobenzene. This first-generation effort constitutes proof of principle. A second objective is optimization of a second-generation synthesis, which also takes advantage of enzymatic oxidation of a commodity chemical, to yield 100 grams of the product. Each of these two syntheses has the potential of producing the substance in fewer than six operations. The best route will be chosen for commercialization, possibly as part of Phase II of the Idea to Innovation program. Any intermediate produced during the synthesis resembling oseltamivir in structure or functionality will be screened for antiviral activity, and any active compound will be subjected to lead optimization. Structure-activity relationships will be investigated in collaboration with an industrial partner during Phase II.
Once optimized, these first- and second-generation efforts hold great potential as means of large-scale supply of this important medicinal agent. It is estimated that the project will be completed in 12 months with the effort of two postdoctoral fellows.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
370928-2008
Name nom
Hudlicky, Tomas
Department département
Chemistry
Organization id
22
Institution établissement
Brock University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
123930
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
Efficient chemoenzymatic synthesis of Tamiflu: Proof of principle, optimization , and development of the shortest commercial synthesis
Keyword
NA
Application summary
The proposed project is concerned with providing a short synthesis of oseltamivir phosphate (Tamiflu) with potential for producing this important antiviral agent on a commercial scale. Tamiflu is one of the few compounds effective against H5N1 influenza virus, and many world governments have stockpiled it as insurance in the event of a major breakout of avian or other forms of influenza. The amounts required for Canada and the U.S. have been estimated at 25 tons of the raw drug. Current commercial syntheses, and several academic efforts, produce Tamiflu in sequences ranging from 8 to 21 steps. Almost all syntheses originate from either natural products or other chiral pool reagents.
The first objective of the project to optimize an eight-step first-generation synthesis, recently accomplished in our laboratory, to a scale of 100 grams of Tamiflu. Provision of detailed experimental procedures will make it possible for a large-scale process group to take the scale to kilogram level and beyond. The synthesis begins with the enzymatic oxidation of a commodity chemical, bromobenzene. This first-generation effort constitutes proof of principle. A second objective is optimization of a second-generation synthesis, which also takes advantage of enzymatic oxidation of a commodity chemical, to yield 100 grams of the product. Each of these two syntheses has the potential of producing the substance in fewer than six operations. The best route will be chosen for commercialization, possibly as part of Phase II of the Idea to Innovation program. Any intermediate produced during the synthesis resembling oseltamivir in structure or functionality will be screened for antiviral activity, and any active compound will be subjected to lead optimization. Structure-activity relationships will be investigated in collaboration with an industrial partner during Phase II.
Once optimized, these first- and second-generation efforts hold great potential as means of large-scale supply of this important medicinal agent. It is estimated that the project will be completed in 12 months with the effort of two postdoctoral fellows.